Clinical trials have shown that SGLT2 inhibitors reduce the risk of both microvascular complications, such as diabetic nephropathy [17,18], and macrovascular events, including cardiovascular disease [1,19], ultimately contributing to improved quality of life in patients with T2DM. The gene discussed is SLC5A2; the disease is cardiovascular disorder.